Answers are grounded in this paper and cite their sources.
In a recent study published in Cancer Discovery , Haldar and colleagues report the first-in-human evaluation of a pooled mutant (Kirsten rat sarcoma viral oncogene homolog) KRAS peptide vaccine in individuals at high risk of pancreatic ductal adenocarcinoma (PDAC). Vaccination induced broad and durable mutant KRAS-specific T-cell responses in most participants, providing a proof of concept for targeting oncogenic driver mutations before invasive pancreatic cancer develops. 1
No takes yet. Share an insight, caveat, or question.
Holmström et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: